Navigation Links
Edison Pharmaceuticals to Provide Expanded Access to EPI-743 for Mitochondrial Disease
Date:6/8/2011

dministration

— Clinicaltrials.gov

EPI-743

EPI-743 is an orally absorbed small molecule that readily crosses into the central nervous system. It works by targeting an enzyme NADPH quinone oxidoreductase 1 (NQO1). Its mode of action is to synchronize energy generation in mitochondria with the need to counter cellular redox stress(1). EPI-743 is in phase 2B/3 pivotal clinical trials.

About Inherited Mitochondrial Disease

Inherited mitochondrial diseases are genetic disorders that share as a common link defects in how cells make and regulate energy. They can arise through defects in genes located in the nucleus or mitochondria. An estimated 2,000 defects in nuclear DNA and 200 defects in mitochondrial DNA have been identified that are pathogenic(2).

Inherited mitochondrial diseases are clinically diverse and poorly understood. They can affect virtually any organ system in the body. As the brain and muscle tissue use an extraordinary amount of energy, they are dramatically affected by these disorders. Mitochondrial diseases often present with central nervous system manifestations, but they also result in a variety of other significant clinical signs that include diabetes, heart failure, liver failure, deafness, blindness, renal insufficiency, and muscle weakness and fatigue.

The incidence of mitochondrial disease is estimated at 1-5 in 10,000. However, this number may underestimate the true number of people with mitochondrial disease. While new genetic screening tools have made detection of mitochondrial disease possible, the majority of individuals with a clinical diagnosis of mitochondrial disease may not have a confirmatory genetic diagnosis. Some estimates place the number of clinically diagnosed mitochondrial disease patients without a genetic diagnosis– so called mitochondrial syndromes– at 10 times the incidence of genetically defined disease.

Science today is at the front
'/>"/>

SOURCE Edison Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Edison Pharmaceuticals Announces FDA Grants EPI-743 Orphan Drug Designation
2. Samsung Medison Pledges to Become a World-Class Medical Device Company
3. NOMAD by Aribex Receives Edison Best New Product Award
4. Quest Diagnostics Honored for Diagnostic Innovation at 2011 Edison Awards
5. Osteotechs Plexur M® Technology Wins Thomas Alva Edison Patent Award from the New Jersey Research and Development Council
6. Zargis Medical Strikes Gold at 2010 Edison Awards
7. Orthocare Innovations Compas and Smart Pyramid Recognized at Edison Best New Product Awards
8. Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards
9. Edison Pharma Hits Milestone as A0001 Enters Phase 1 Clinical Development
10. Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA
11. Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex ... it expects to report results for the fourth quarter ... release announcing the results is scheduled for release after ... http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will hold a conference ... for the fourth quarter and twelve months ended December ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new ... targeting guide with accompanying instrumentation to place and insert ... to the soft tissue (e.g. ligament) repair or reconstruction ... repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ... the anatomical reduction (spacing) of the scaphoid and lunate ...
(Date:1/14/2014)... 2014   Oligomerix, Inc. , a privately ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... headquarters to Valhalla, NY ... agreement for additional laboratory space at New York ... on the development of small molecule drugs aimed ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... August 27 , - Oralair(R) Grasses 300IR Highly ... Allergen Challenge Chamber, Stallergenes S.A. announces the highly ... Challenge Chamber (ACC)., The study on Oralair(R) Grasses ... different treatment durations: 1 week, 1 month,2 and 4 ...
... INDIANAPOLIS, Aug. 26 Semafore Pharmaceuticals Inc.,announced data ... in Cancer in Washington, D.C., showing additional antiangiogenic,activity ... both VEGF and Bv8 signaling., PI3K is ... /mTOR pathway that,has been shown to play a ...
Cached Medicine Technology:Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... 1 More than 125 leaders,from throughout the ... joined,together to support a multi-year, statewide campaign to ... campaign, launched by Nemours Health,and Prevention Services (NHPS), ... health professionals, parents, and other leaders to,improve the ...
... Team will develop "probes" to aid in the ... 1 Southern Research,Institute --- a not-for-profit organization ... of preclinical drug discovery and drug development --,today ... Institute of,Mental Health (NIMH) to identify small molecules ...
... GARDNER, Mass., Oct. 1 Precision Optics,Corporation, Inc. (OTC ... the fourth quarter and fiscal year ended,June 30, 2007. ... the quarter ended June 30, 2007, revenues were,$1,111,833 compared ... increase,of 94%. This represents the highest quarterly revenue in ...
... Oct. 1 Mylan Laboratories Inc.,(NYSE: MYL ) ... Vice,President and Treasurer, effective October 22, 2007. Mr. Byala ... with responsibility for,treasury planning in both New York and ... in various treasury positions of increasing responsibility.,Prior to Pfizer, ...
... Oct. 1 A healthy diet and,good nutrition are ... The Pennsylvania Dental Association (PDA) stresses the,importance of watching ... Think of your body as a complex machine. The ... up" affect your general health and that of your,teeth ...
... 1 Bally Total Fitness announced,that it has ... private company,just over two months after filing for ... funded by Harbinger Capital Partners,Master Fund I, Ltd. ... became effective today. Harbinger invested approximately $233.6 ...
Cached Medicine News:Health News:More than 125 State Leaders - Including Governor, Lt. Governor, and Congressional Delegation - Endorse Campaign to Make Delaware's Kids the Healthiest in the Nation 2Health News:More than 125 State Leaders - Including Governor, Lt. Governor, and Congressional Delegation - Endorse Campaign to Make Delaware's Kids the Healthiest in the Nation 3Health News:Southern Research Institute's Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding 2Health News:Southern Research Institute's Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding 3Health News:Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years 2Health News:Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years 3Health News:Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years 4Health News:Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years 5Health News:Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years 6Health News:Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years 7Health News:Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years 8Health News:Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer 2Health News:PDA Stresses Importance of Good Nutrition 2Health News:Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds 2Health News:Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: